Profiles for companies starting with 'n'
✉ Email this page to a colleague
Drugs and US Patents for n
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-001 | Sep 20, 2019 | RX | Yes | Yes | 11,759,501 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novo | WEGOVY | semaglutide | TABLET;ORAL | 218316-001 | Dec 22, 2025 | RX | Yes | Yes | 12,396,953 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Noven | MINIVELLE | estradiol | FILM, EXTENDED RELEASE;TRANSDERMAL | 203752-003 | Oct 29, 2012 | AB3 | RX | Yes | No | 8,231,906 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-002 | Jun 4, 2021 | RX | Yes | Yes | 9,764,003 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novo | OZEMPIC | semaglutide | TABLET;ORAL | 213051-005 | Dec 9, 2024 | RX | Yes | Yes | 8,129,343 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | 12,295,988 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Neurelis Inc | VALTOCO | diazepam | SPRAY;NASAL | 211635-001 | Jan 10, 2020 | RX | Yes | No | 11,793,786 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
